• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Points Of View

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Achieving Biologics manufacturing milestones using a systemic approach to Technology Transfer

Learn how Syngene achieves manufacturing milestones in Biologics using a systemic approach to 100% ‘first-time right’ technology transfer.


Manufacturing vaccines during COVID-19

How and why CROs/CDMOs are better positioned to bridge the gap between vaccine demand and supply, safely and at speed.

Combating COVID-19 - The Oligonucleotide Way

Synthetic oligonucleotides have emerged as an important modality for diagnostics and potential therapy option for COVID-19.

Has the Age of Antisense Oligonucleotides Finally Arrived

Antisense Oligonucleotides is gaining momentum as a treatment modality to correct faulty protein expression by non-conventional means i.e., splicing modifications.

Your pre-clinical toxicology program needs a strategy

At Syngene, we have developed a roadmap across pre-IND, IND and NDA that seamlessly integrate the various pre-clinical studies — thereby accelerating the initiation of Clinical trials.

The Dedicated Center- Outsourcing Answer to the Innovation and ROI Challenge in the Biopharmaceutical Industry

Syngene’s dedicated  model is the equivalent of having access to a full-fledged pharma company, housed in a single campus with capabilities across small and large molecules.

Proactive COVID-19 testing

By identifying COVID-19 positive cases early on,  particularly those that are asymtomatic,  we can restrict further transmission of this deadly virus.

How Integrated CMC Can Help Expedite Early Phase Development of Small Molecules – A CRO Perspective

Syngene’s 7-phase integrated CMC strategy helps expedite IND/IMPD filings and FIH studies. As a result, the  typical time from clinical candidate to regulatory filing is  just 11 months.

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details